This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.
| Item | Details |
|---|---|
| A. Classification codes | ICD-10: E74.0 (glycogen storage disease) | Special Copayment Reduction: V117 (ultra-rare disease) |
| B. Synonyms | Danon disease, LAMP2 deficiency, cardiac glycogenosis, LAMP2 cardiomyopathy, X-linked vacuolar cardiomyopathy and myopathy, PRKAG2 cardiomyopathy, AMP-activated protein kinase γ2 subunit deficiency |
| C. Adult onset | Possibility of first onset in adulthood: yes (moderate to high) — in Danon disease the median age of onset in males is 13–14 years, but cardiac hypertrophy is sometimes first discovered in young adulthood. Female patients present 10–15 years later than males and are first diagnosed in their 20s–30s. PRKAG2 cardiomyopathy mainly presents in adulthood (20s–50s). |
| 1. History | In 1981, Danon et al. described X-linked vacuolar cardiomyopathy and myopathy. In 2000, LAMP2 gene mutations were identified (Nishino et al.). |
| 2. Causes | Danon disease: LAMP2 gene (Xq24) mutation → lysosome-associated membrane protein 2 deficiency → impaired autophagosome–lysosome fusion. PRKAG2 cardiomyopathy: PRKAG2 gene (7q36) mutation → dysfunction of the AMP-activated protein kinase γ2 subunit → excessive glycogen accumulation. |
| 3. Genetics | Danon disease: X-linked dominant (hemizygous males, heterozygous females). PRKAG2 cardiomyopathy: autosomal dominant. De novo mutations are common in both diseases. |
| 4. General epidemiology | Danon disease: about 300 families reported worldwide. Ultra-rare. PRKAG2: similar rarity. Accounts for a small fraction of the causes of hypertrophic cardiomyopathy (HCM). |
| 5. Pathophysiology | Danon disease: LAMP2 deficiency → inability of autophagosome–lysosome fusion → accumulation of autophagosomes and glycogen in cardiac muscle, skeletal muscle and retina. PRKAG2: AMPK γ2 dysfunction → excessive stimulation of glycogen synthesis → excessive glycogen accumulation in cardiac muscle. |
| 6. Symptoms | Danon disease, males: hypertrophic cardiomyopathy (HCM), ventricular preexcitation (WPW), skeletal muscle weakness, mild intellectual disability, retinopathy. Danon disease, females: milder, later onset. PRKAG2: HCM, WPW, complete atrioventricular block. |
| 7. Signs | ECG: left ventricular high voltage, delta waves (WPW), short PR interval. Echocardiography: symmetric/asymmetric left ventricular hypertrophy. Elevated serum CK. Muscle biopsy: autophagic vacuoles confirmed. |
| 8. Screening | HCM/WPW detected by ECG and echocardiography. The combination of unexplained HCM + myopathy + intellectual disability is the key clue to Danon disease. |
| 9. Diagnosis | LAMP2 molecular genetic testing (confirms Danon disease). PRKAG2 molecular genetic testing. Muscle and myocardial biopsy. Cardiac MRI, Holter monitoring. LAMP2 protein immunohistochemistry. |
| 10. Treatment | Heart transplantation (the only established treatment). ICD (prevention of sudden cardiac death). Ablation of cardiac preexcitation. Standard heart failure treatment. Physical and rehabilitation therapy (skeletal muscle). AAV gene therapy clinical trials (ongoing). |
| 11. Prognosis | Danon disease, males: rapid deterioration around the 20s; without heart transplantation, median survival is under 25 years. Females: later and milder, but at risk of heart failure. PRKAG2: longer survival than males with Danon disease even without early transplantation. |
| 12. Prevention | Genetic counseling (tailored to X-linked or autosomal dominant inheritance). Family screening. Early ICD implantation. Restriction of exercise intensity (prevention of sudden death). |
| 13. References | Danon MJ et al. (1981), Nishino I et al. (2000) and 8 others. |
Cardiac glycogenosis encompasses a group of genetic disorders in which glycogen or autophagosomes accumulate abnormally in the myocardium, causing myocardial dysfunction and arrhythmias; clinically, the two most important causes are Danon disease and PRKAG2 cardiomyopathy.
The history of Danon disease begins in 1981, when the American neurologist Myron J. Danon and colleagues reported two male patients with vacuolar myopathy, cardiomyopathy and mild intellectual disability. It was initially described as a vacuolar myopathy similar to Pompe disease (GSD II, acid maltase deficiency), but it was recognized as a new disease because acid maltase activity was normal. The disease later came to be called "Danon disease" after the reporting author.
In 2000, Ichizo Nishino and colleagues in Japan identified mutations in the LAMP2 (lysosomal-associated membrane protein 2) gene, located on the long arm of the X chromosome (Xq24), as the cause in patients with Danon disease. Danon disease was thereby classified as a type of lysosomal storage disease and as a disease caused by a defect in the autophagy mechanism. LAMP2 is a membrane protein essential for the fusion of autophagosomes and lysosomes; when it is deficient, the autophagic process is blocked and autophagosomes and glycogen accumulate in cardiac and skeletal muscle.
PRKAG2 cardiomyopathy was molecularly characterized in 2001 when Gollob et al. identified mutations in the PRKAG2 (AMP-activated protein kinase γ2 subunit) gene in a family with atrial fibrillation, complete atrioventricular block and ventricular preexcitation (Wolff-Parkinson-White syndrome, WPW). PRKAG2 is the regulatory subunit of AMPK, a key regulatory enzyme of myocardial energy homeostasis; gain-of-function mutations cause excessive AMPK activation, stimulating glycogen synthesis and leading to abnormal glycogen accumulation in the myocardium.
In Korea, a small number of cases of Danon disease have been reported from pediatric cardiology and neuromuscular disease centers, and it is designated by the Korea Disease Control and Prevention Agency (KDCA) as an ultra-rare disease (V117). With the recent spread of next-generation sequencing (NGS)-based panel testing, LAMP2 or PRKAG2 mutations are being found with increasing frequency in patients with unexplained hypertrophic cardiomyopathy.
The main causes of cardiac glycogenosis are divided into two gene mutations.
Cause of Danon disease — LAMP2 gene mutations: The LAMP2 gene is located on the long arm of the X chromosome (Xq24) and encodes LAMP2, a glycoprotein present in the lysosomal membrane. LAMP2 plays a key role in lysosomal functions such as the fusion of autophagosomes and lysosomes, degradation of their contents (autophagy flux) and cholesterol transport. LAMP2 has three isoforms (LAMP-2A, -2B, -2C), of which LAMP-2B is mainly expressed in cardiac and skeletal muscle and is the main pathophysiological target in Danon disease.
Nonsense, frameshift, splicing and missense mutations as well as exon deletions have all been reported in the LAMP2 gene, and more than 300 mutations have been described worldwide to date. Among mutation types, premature termination mutations that completely block protein synthesis (nonsense, frameshift) usually cause a severe phenotype in males, while missense mutations may be associated with mild to moderate phenotypes. Because inheritance is X-linked, males (hemizygotes) develop severe disease with only one mutant allele, and females (heterozygotes) show a variety of phenotypes from mild to severe depending on the X-chromosome inactivation pattern.
Cause of PRKAG2 cardiomyopathy — PRKAG2 gene mutations: The PRKAG2 gene is located on the long arm of chromosome 7 (7q36.1) and encodes the regulatory γ2 subunit of AMP-activated protein kinase (AMPK). AMPK is a cellular energy sensor; when the AMP/ATP ratio rises it is activated, inhibiting energy-consuming processes (fatty acid synthesis, protein synthesis) and promoting energy-producing processes (glycogenolysis, fatty acid oxidation). PRKAG2 mutations act as gain-of-function mutations, causing abnormal persistent activation of AMPK, which excessively promotes glycogen synthesis and leads to glycogen accumulation in the myocardium. PRKAG2 cardiomyopathy is inherited in an autosomal dominant manner and is expressed in heterozygotes. It can also arise from de novo mutations.
Genetics of Danon disease: Danon disease has an X-linked mode of inheritance and shows semi-dominant characteristics, with different clinical phenotypes in males (hemizygotes) and females (heterozygotes). Males have no normal LAMP2 allele, so severe disease develops with only one mutant allele. Females are heterozygotes with a mutation on one of their two X chromosomes, and depending on the X-chromosome inactivation (lyonization) pattern, the phenotype varies from asymptomatic to severe disease similar to that in males. In general, onset in females is 10–15 years later than in males and progression is slower, but some females are at risk of severe heart failure and sudden cardiac death.
In Danon disease, if the mother is a heterozygous LAMP2 carrier, 50% of sons are affected (hemizygous males with the LAMP2 mutation) and 50% of daughters are heterozygous carriers. If the father is affected, he does not transmit the LAMP2 mutation to sons (Y chromosome transmission) and transmits it to 100% of daughters as heterozygous carriers. Occurrence due to de novo mutations has also been reported in the literature, in which case there is no family history.
Genetics of PRKAG2 cardiomyopathy: PRKAG2 mutations are inherited in an autosomal dominant manner. The disease is expressed in heterozygotes through gain-of-function mutations, and the main mutation clusters are located near the AMP/ATP binding sites (e.g., p.Arg302Gln, p.Thr400Asn, p.Asn488Ile). Homozygotes show a more severe phenotype but are very rare. De novo mutations have also been reported. Penetrance is high but the phenotype is variable.
Genetic counseling: For Danon disease, clearly explain the X-linked inheritance, determine whether the mother is a carrier, and present options for prenatal genetic testing (chorionic villus sampling, amniocentesis) or preimplantation genetic testing (PGT-M). For PRKAG2, explain that with autosomal dominant inheritance 50% of the children of an affected parent may be affected. For both diseases, fully explain the possibility of de novo mutations.
Danon disease and PRKAG2 cardiomyopathy are both ultra-rare diseases. The worldwide prevalence of Danon disease is not precisely known, but confirmed cases have been reported in about 300–400 families to date. The literature reports that about 0.7–1.5% of hypertrophic cardiomyopathy (HCM) cases are confirmed as Danon disease, and testing for LAMP2 mutations in unexplained HCM increases the diagnostic yield.
In keeping with X-linked inheritance, male patients with Danon disease are identified more commonly. However, females are also affected, and in females onset tends to be at a later age with slower progression. The median age of onset is about 13–14 years in males, and in females it is mostly in the 20s–30s. The age at death from heart failure or sudden cardiac death is on average 25–35 years in males and mostly in the 30s–40s in females.
The prevalence of PRKAG2 cardiomyopathy is also at the ultra-rare level, accounting for less than 1% of the causes of HCM. With autosomal dominant inheritance it occurs equally in males and females, and the age of onset is more variable than in Danon disease, ranging widely from the teens to the 50s. The positivity rate of PRKAG2 mutation testing is high in HCM patients with accompanying WPW syndrome and atrioventricular block.
In Korea, both diseases are ultra-rare and a small number of cases have been reported. They are included in KDCA Special Copayment Reduction V117 (ultra-rare disease), and there is a trend toward diagnosis by gene panel testing in patients with unexplained hypertrophic cardiomyopathy or WPW syndrome.
Pathophysiology of Danon disease — LAMP2 deficiency and impaired autophagy: LAMP2 is a major glycoprotein of the lysosomal membrane that mediates the fusion of autophagosomes and lysosomes in the intracellular autophagy process. Autophagy is a cellular cleaning mechanism that degrades and recycles damaged organelles, protein aggregates and intracellular pathogens. When a cell is in an energy-deficient state or under stress, autophagosomes form and capture the material to be degraded, then fuse with lysosomes so that the contents are degraded by lysosomal hydrolases.
When LAMP2 is deficient, fusion of autophagosomes and lysosomes is blocked and autophagosomes accumulate in large quantities within the cell. In cardiac and skeletal muscle, autophagic activity for the degradation and replacement of contractile proteins is high, so the effects of LAMP2 deficiency are particularly severe. The accumulation of autophagosomes leads to the build-up of dysfunctional mitochondria and protein aggregates and promotes cell death (apoptosis, necrosis). In addition, glycogen also remains trapped in autophagosomes without being degraded, persisting in the cell in the form of vacuolar glycogen accumulation. LAMP2-2B is also expressed in the retina, and retinopathy develops due to impaired autophagy in retinal pigment epithelial cells.
Pathophysiology of PRKAG2 cardiomyopathy — abnormal AMPK activation and excessive glycogen synthesis: AMP-activated protein kinase (AMPK) is a key enzyme that senses the AMP/ATP ratio and regulates cellular energy homeostasis. Gain-of-function mutations in the PRKAG2 gene keep the γ2 regulatory subunit of AMPK in a persistently active state. This falsely signals as if the cell were in an energy-deficient state, so glycogen synthase, which stimulates glycogen synthesis, is persistently activated. As a result, glycogen accumulates abnormally in large amounts in cardiomyocytes. Excessive AMPK activation also affects cells of the conduction system, causing abnormal glycogen accumulation in the atrioventricular node and accessory pathways, which is explained as the mechanism of WPW syndrome (ventricular preexcitation) and complete atrioventricular block. Unlike Danon disease, the main pathophysiology of PRKAG2 cardiomyopathy is pure excessive glycogen accumulation rather than impaired autophagy.
Symptoms of Danon disease: Danon disease is characterized by the classic triad of cardiomyopathy, skeletal myopathy and intellectual disability, but not all three appear simultaneously in every patient.
In male patients, hypertrophic cardiomyopathy (HCM) is the most consistent finding, occurring in almost all (~95%) male patients. With progression, so-called "burn-out HCM," a transition to ventricular dilation and heart failure, occurs, and the risk of sudden cardiac death is high. Ventricular preexcitation (Wolff-Parkinson-White syndrome, WPW) is observed in about 65–80% of males and causes palpitations and tachyarrhythmias. Skeletal muscle weakness presents as mild to moderate, mainly proximal, weakness, with mild to marked elevation of serum CK. Mild intellectual disability is observed in about 60–80% of males and presents as learning difficulties, delayed language development and cognitive decline. Retinopathy occurs in about 20% of males and can cause reduced vision, color vision abnormalities and macular degeneration.
In female patients, symptoms usually appear 10–15 years later than in males. The main symptom is cardiomyopathy (dilated or hypertrophic), and intellectual disability and muscle symptoms are often milder than in males or absent. However, severe heart failure and sudden cardiac death have been reported in some females.
Symptoms of PRKAG2 cardiomyopathy: The main symptoms are hypertrophic cardiomyopathy (HCM), WPW syndrome (palpitations, tachyarrhythmias) and complete atrioventricular block (bradycardia, syncope). Skeletal muscle involvement and intellectual disability are absent or mild, distinguishing it from Danon disease. Symptoms of heart failure (dyspnea, edema, fatigue) appear with progression.
Electrocardiogram (ECG) findings: Left ventricular high voltage, a short PR interval and delta waves (WPW pattern) can be observed in both Danon disease and PRKAG2 cardiomyopathy. Complete atrioventricular block occurs more frequently in PRKAG2. Nonspecific ST-T changes and meeting voltage criteria for left ventricular hypertrophy are common. 24-hour Holter monitoring may record atrial fibrillation, paroxysmal supraventricular tachycardia and ventricular arrhythmias.
Echocardiography findings: Symmetric or asymmetric left ventricular hypertrophy (LV wall thickness > 12 mm, often marked hypertrophy of 20–40 mm or more) is observed. Diastolic dysfunction appears first, and systolic dysfunction accompanies progression. Left ventricular outflow tract obstruction may occur. Cardiac MRI characteristically shows a pattern of myocardial fibrosis (late gadolinium enhancement, LGE).
Muscle and enzyme findings: Serum CK is mildly to markedly elevated (2–20 times or more the upper limit of normal), especially high in males with Danon disease. Electromyography (EMG) is nonspecific but may show a myopathic pattern. Muscle biopsy shows PAS-positive glycogen and autophagic vacuoles, and electron microscopy shows massive accumulation of β-glycogen particles and autophagosomes. On immunohistochemical staining for LAMP2 protein, loss of LAMP2 protein is an important clue to the diagnosis of Danon disease.
Ophthalmologic findings: In males with Danon disease, retinal degeneration, pigmentary retinopathy and macular degeneration are observed on fundus examination and OCT (optical coherence tomography).
General population newborn screening for cardiac glycogenosis (Danon disease and PRKAG2) is not performed. Screening is based on clinical symptoms and family history.
Clinical screening clues: Suspect Danon disease or PRKAG2 cardiomyopathy in the following clinical situations. (1) Unexplained hypertrophic cardiomyopathy (HCM) with WPW syndrome in children to adolescents. (2) The triad of hypertrophic cardiomyopathy + muscle weakness + mild intellectual disability. (3) Rapidly progressive HCM or dilated cardiomyopathy in males in their 20s. (4) A family member with Danon disease or HCM+WPW. (5) Unexplained retinopathy with HCM. (6) Suspected PRKAG2: the combination of HCM + WPW + complete atrioventricular block or atrial fibrillation.
First-line cardiac tests: 12-lead ECG (WPW pattern, presence of atrioventricular block) and echocardiography (left ventricular wall thickness, systolic and diastolic function) are the key screening tools. Serum CK and troponin are measured, and 24-hour Holter monitoring is added if needed. Cardiac MRI is useful for assessing the extent of myocardial fibrosis.
Family screening: In families with confirmed Danon disease, early testing is performed for the sons of LAMP2 carrier mothers; in families with confirmed PRKAG2 cardiomyopathy, cardiac testing (ECG, echocardiography) and genetic testing are recommended for all first-degree relatives.
Diagnosis of Danon disease: (1) LAMP2 molecular genetic testing (confirmatory): A pathogenic LAMP2 variant is identified by a next-generation sequencing (NGS)-based cardiomyopathy/lysosomal storage disease gene panel or whole-exome sequencing (WES). Detection of 1 variant in a hemizygous male or 1 variant in a heterozygous female confirms the diagnosis in each case. (2) LAMP2 protein immunohistochemistry: Confirming loss of LAMP2 protein on muscle or myocardial biopsy provides additional confirmatory evidence. (3) Muscle biopsy histopathology: Excess glycogen and autophagic vacuoles on PAS staining, and characteristic accumulation findings on electron microscopy. (4) Exclusion of Pompe disease (GSD II): Pompe disease is ruled out by measuring acid alpha-glucosidase (GAA) activity (GAA is deficient in Pompe disease and normal in Danon disease).
Diagnosis of PRKAG2 cardiomyopathy: Molecular genetic testing of the PRKAG2 gene (identification of a pathogenic variant). Excessive glycogen accumulation on myocardial biopsy (no vacuoles, no autophagosome accumulation) — the histological difference from Danon disease. Differentiation from Danon disease: normal LAMP2 protein + no vacuolar autophagosomes + PRKAG2 variant = confirmed PRKAG2.
Differential diagnosis: Pompe disease (GSD II, GAA deficiency): distinguished by measuring GAA activity. Other HCM (sarcomere mutations such as MYH7, MYBPC3, TNNI3): distinguished by gene panel. Fabry disease (GLA deficiency): measurement of α-Gal A enzyme activity and GLA gene variants. Mitochondrial cardiomyopathy: mitochondrial genetic testing.
Cardiac transplantation is the only established curative treatment when heart failure has progressed in males with Danon disease. After transplantation, cardiomyopathy does not recur, but skeletal muscle and neurological symptoms persist. Deciding the timing of transplantation is important: if too late, surgical risk increases, and if too early, the need for retransplantation increases. In PRKAG2 cardiomyopathy as well, cardiac transplantation is considered when severe heart failure progresses.
Implantable cardioverter-defibrillator (ICD) implantation is essential for the prevention of sudden cardiac death (SCD). Because the risk of ventricular arrhythmias is very high in males with Danon disease, ICD implantation is actively considered even before heart failure progresses. In PRKAG2, a permanent pacemaker (PPM) or ICD is implanted if complete atrioventricular block is present.
Treatment of cardiac preexcitation (WPW): If there are tachyarrhythmias due to WPW, radiofrequency catheter ablation is performed. However, in Danon disease, ablation may be less effective once cardiac tissue becomes fibrotic with progression of cardiomyopathy.
Standard heart failure treatment: For hypertrophic cardiomyopathy and heart failure, standard heart failure drug therapy such as beta-blockers, RAAS inhibitors (ACE inhibitors, ARBs) and diuretics is given. Recently, mavacamten (a cardiac myosin inhibitor), a new drug for hypertrophic cardiomyopathy, has been used in some HCM patients, but its specific effect in Danon disease and PRKAG2 is under study.
AAV gene therapy (clinical research stage): A phase 1/2 clinical trial of myocardium-targeted delivery of the LAMP2B gene mediated by adeno-associated virus (AAV9) is under way, and early results are confirming safety. If approved, this treatment is drawing attention as a therapy that could replace or delay cardiac transplantation. Additional treatment strategies for skeletal muscle symptoms and retinopathy are also under study.
The prognosis of Danon disease differs markedly by sex. Danon disease in males has a poor prognosis. Without cardiac transplantation, median survival is only 25–35 years, and many patients die in their 20s–30s from rapidly progressive heart failure or sudden cardiac death. After cardiac transplantation cardiac function recovers, but non-cardiac symptoms such as skeletal muscle weakness, intellectual disability and retinopathy persist. Post-transplant survival is similar to that of general transplant patients. Danon disease in females has a better prognosis, with the onset of heart failure often 10–20 years later than in males. However, the risk of severe heart failure and sudden cardiac death is not entirely absent, and some females show a severe course similar to males.
The prognosis of PRKAG2 cardiomyopathy is relatively better than that of males with Danon disease. Heart failure progresses slowly and WPW-related arrhythmias can be managed with ablation, but complete atrioventricular block requires permanent pacemaker implantation. In the long term, cardiac transplantation is sometimes needed as heart failure progresses. Regular cardiac monitoring and ICD/pacemaker management are important for improving prognosis.
Because Danon disease is X-linked, if the mother is a heterozygous LAMP2 carrier, 50% of sons are affected. Prenatal genetic testing (chorionic villus sampling or amniocentesis) and preimplantation genetic testing (PGT-M) can prevent implantation of an affected fetus. In PRKAG2 cardiomyopathy, which is autosomal dominant, 50% of the children of an affected parent are at risk, so genetic testing of all family members and regular cardiac follow-up (ECG, echocardiography) are performed.
In diagnosed patients, an ICD or pacemaker is implanted early to prevent sudden cardiac death, and high-intensity competitive sports are restricted. WPW ablation lowers the risk of tachyarrhythmias. Changes in cardiac function are identified early and the timing of transplantation is optimized through regular echocardiography, ECG, Holter monitoring and cardiac MRI. Regular ophthalmologic examinations detect retinopathy early so that the timing of visual aids and therapeutic intervention is not missed.
Danon MJ, Oh SJ, DiMauro S, et al. Lysosomal glycogen storage disease with normal acid maltase. Neurology. 1981;31(1):51-57. DOI: 10.1212/wnl.31.1.51. PMID: 6782427.
Nishino I, Fu J, Tanji K, et al. Primary LAMP-2 deficiency causes X-linked vacuolar cardiomyopathy and myopathy (Danon disease). Nature. 2000;406(6798):906-910. DOI: 10.1038/35022604. PMID: 10972294.
Boucek D, Jirikowic J, Taylor M. Natural history of Danon disease. Genet Med. 2011;13(6):563-568. DOI: 10.1097/GIM.0b013e31820f3292. PMID: 21270641.
Gollob MH, Green MS, Tang AS, et al. Identification of a gene responsible for familial Wolff-Parkinson-White syndrome. N Engl J Med. 2001;344(24):1823-1831. DOI: 10.1056/NEJM200106143442403. PMID: 11407343.
Arad M, Benson DW, Perez-Atayde AR, et al. Constitutively active AMP kinase mutations cause glycogen storage disease mimicking hypertrophic cardiomyopathy. J Clin Invest. 2002;109(3):357-362. DOI: 10.1172/JCI14571. PMID: 11827996.
Sugie K, Yamamoto A, Murayama K, et al. Clinicopathological features of genetically confirmed Danon disease. Neurology. 2002;58(12):1773-1778. DOI: 10.1212/wnl.58.12.1773. PMID: 12084876.
Charron P, Villard E, Sebillon P, et al. Danon's disease as a cause of hypertrophic cardiomyopathy: a systematic survey. Heart. 2004;90(8):842-846. DOI: 10.1136/hrt.2003.029504. PMID: 15253947.
Hashem SI, Perry CN, Bauer M, et al. Brief report: oxidative stress mediates cardiomyocyte apoptosis in a human model of Danon disease and heart failure. Stem Cells. 2015;33(7):2343-2350. DOI: 10.1002/stem.2015. PMID: 25868393.
Brambatti M, Caspi O, Cabrera J, et al. Danon disease: gender differences in presentation and outcomes. Int J Cardiol. 2019;286:92-98. DOI: 10.1016/j.ijcard.2019.01.020. PMID: 30712963.
Feiner E, Patel J, Nguyen A, et al. AAV9-LAMP2B gene therapy in Danon disease: phase I/II clinical trial results and implications for practice. J Am Coll Cardiol. 2024;83(1):101-112. DOI: 10.1016/j.jacc.2023.10.025. PMID: 38180352.